Lerivon

Mianserin hydrochloride, the active ingredient in Lerivon, is a tetracyclic antidepressant presented as an oral dosage form for oral use. It is prescribed for the treatment of major depressive disorder in adult patients and works by modulating central neurotransmitter activity. The compound is marketed in the European Union and meets quality standards for pharmaceutical distribution.

GNH USA supplies Lerivon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring reliable global access to this medication and patients.

Lerivon (mianserin hydrochloride) is used in the management of depressive disorders and related conditions. - Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Anxiety associated with depression: alleviates anxiety symptoms that co‑occur with depressive episodes. - Insomnia linked to depression: provides sedative effects that can improve sleep quality in depressed individuals.

Mianserin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dry mouth: reduced salivation leading to a dry sensation. - Constipation: difficulty passing stools. - Weight gain: increase in body weight over time. - Dizziness: sensation of light‑headedness or unsteadiness. - Increased appetite: heightened desire for food.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Seizures: occurrence of convulsive episodes. - Cardiac arrhythmia: irregular heart rhythm, including QT prolongation. - Severe hypotension: marked drop in blood pressure. - Hepatic injury: signs of liver dysfunction. - Blood dyscrasias: abnormal blood cell counts.

Before initiating therapy with Lerivon, several precautions should be considered to ensure safe use. - Monitor blood counts: obtain baseline and periodic complete blood count tests. - Assess cardiovascular status: evaluate for history of arrhythmias or heart disease. - Evaluate liver function: perform liver enzyme tests prior to treatment. - Avoid abrupt discontinuation: taper the dose under medical supervision to prevent withdrawal. - Use caution in elderly: increased sensitivity to sedation and orthostatic effects. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Mianserin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertensive crisis. - Selective serotonin reuptake inhibitors (SSRIs): potential serotonin syndrome. - Other central nervous system depressants: enhanced sedation and respiratory depression. - Antihistamines: additive sedative effects. - Tricyclic antidepressants: increased risk of cardiac toxicity.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may raise mianserin plasma levels. - Antihypertensive agents: possible additive blood pressure lowering. - Alcohol: can intensify drowsiness and impair coordination. - Anticholinergic drugs: may exacerbate dry mouth and constipation. - Warfarin: monitor INR for potential changes in anticoagulation.